ACI's Fraud and Abuse in the Sales and Marketing of Drugs and Medical Devices Conference

On July 20, Washington, D.C. litigation head Jennifer Bragg joined a panel discussion during ACI’s “Fraud and Abuse in the Sales and Marketing of Drugs and Medical Devices Conference.” Ms. Bragg's panel explored (i) the latest federal fraud and abuse pitfalls in certain precision medicine arrangements (ii) a recent advisory opinion by the Office of Inspector General (OIG) for the U.S. Department of Health and Human Services highlighting pharmaceutical company kickback risks associated with incorporating free genetic testing into their marketing plans and (iii) recent OIG guidance on when a pharmaceutical manufacturer may provide financial assistance to a patient, among other topics.